Synaptogenix (NASDAQ:TAOX) Announces Earnings Results

Synaptogenix (NASDAQ:TAOX) announced its quarterly earnings results on Tuesday. The company reported $1.03 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of ($2.46) million for the quarter.

Synaptogenix Stock Up 6.0%

TAOX traded up $0.32 on Tuesday, reaching $5.69. The company had a trading volume of 73,845 shares, compared to its average volume of 235,053. Synaptogenix has a 1 year low of $1.84 and a 1 year high of $11.98. The stock has a market capitalization of $42.38 million, a PE ratio of -0.28 and a beta of 1.99. The stock has a 50-day moving average price of $4.65 and a 200-day moving average price of $5.82.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TAOX. Wall Street Zen raised Synaptogenix from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.